NCT07099898 - A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

September 2, 2026

Study Completion Date

September 11, 2028

Conditions

Neoplasms, Lung

Interventions

BIOLOGICAL

GSK5764227

GSK5764227 will be administered

DRUG

Topotecan

Topotecan will be administered

Trial Locations (14)

2065

RECRUITING

GSK Investigational Site, St Leonards

2148

RECRUITING

GSK Investigational Site, Blacktown

6009

RECRUITING

GSK Investigational Site, Nedlands

10408

RECRUITING

GSK Investigational Site, Gyeonggi-do

13620

RECRUITING

GSK Investigational Site, Seongnam-si Gyeonggi-do

44033

RECRUITING

GSK Investigational Site, Ulsan

51472

RECRUITING

GSK Investigational Site, Changwon

C1426ABP

RECRUITING

GSK Investigational Site, Buenos Aires

C1012AAR

RECRUITING

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

C1426AGE

RECRUITING

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

S2000 DEJ

RECRUITING

GSK Investigational Site, Rosario

K1H 8L6

RECRUITING

GSK Investigational Site, Ottawa

812-8582

RECRUITING

GSK Investigational Site, Fukuoka

594-0073

RECRUITING

GSK Investigational Site, Osaka